{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:10:51Z","timestamp":1790727051999,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Menin inhibitors are a class of targeted agents that exemplify how a deeper understanding of leukemia pathogenesis can unify seemingly distinct genetic acute leukemia subgroups under a common therapeutic strategy. In particular, acute leukemia with NPM1 mutations (NPM1m) and KMT2A rearrangements (KMT2Ar) represent the primary targets of this emerging drug class. Acute myeloid leukemia (AML) with NPM1m\u2014which accounts for approximately 30% of AML cases and AML or acute lymphoblastic leukemia (ALL) with KMT2Ar\u2014and is present in 5\u201310% of cases, shares a common pathogenetic mechanism: the aberrant activation of the MEIS1\u2013HOXA axis. These leukemic subsets are associated with poor prognosis, particularly in the relapsed\/refractory (R\/R) setting. For KMT2Ar AML, the prognosis is especially dismal, with a median overall survival (OS) of 2.4 months and a complete remission (CR) rate of only 5%. In NPM1m AML, intensive chemotherapy achieves remission in approximately 80% of cases, but relapse remains a major challenge, occurring in nearly 50% of patients. Relapsed NPM1m AML is linked to a poor prognosis, with a median OS of 6.1 months (12-month OS: 30%) and a median relapse-free survival (RFS) of 5.5 months (12-month RFS: 34%). Menin inhibitors directly target the leukemogenic transcriptional program driven by HOX and MEIS1, disrupting oncogenic signaling and offering a promising therapeutic approach for these high-risk patients. This class of agents has rapidly progressed through clinical development, showing promising antileukemic activity in both treatment-na\u00efve and R\/R AML. Currently, six menin inhibitors are in clinical evaluation as monotherapy or in combination regimens: revumenib, ziftomenib, bleximenib (previously JNJ-75276617), enzomenib (previously DSP-5336), DS-1594, and BMF-219. In this review, we critically analyze the clinical development and therapeutic potential of the four most extensively studied menin inhibitors\u2014revumenib, ziftomenib, bleximenib, and enzomenib. We discuss their efficacy, safety profiles, and potential roles within the current treatment algorithm. The continued clinical evaluation of menin inhibitors may redefine treatment paradigms for NPM1m and KMT2Ar AML and other acute leukemia with the aberrant MEIS1-HOXA axis, offering new hope for patients with limited therapeutic options.<\/jats:p>","DOI":"10.3390\/diseases13070227","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:56:14Z","timestamp":1753084574000},"page":"227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4703-6280","authenticated-orcid":false,"given":"Martina","family":"Canichella","sequence":"first","affiliation":[{"name":"Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia L. e A. Ser\u00e0gnoli, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Mazzone","sequence":"additional","affiliation":[{"name":"Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"de Fabritiis","sequence":"additional","affiliation":[{"name":"Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy"},{"name":"Department of Biomedicina e Prevenzione, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJMc1608739","article-title":"Genomic classification in acute myeloid leukemia","volume":"375","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","article-title":"Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.2009.25.1496","article-title":"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study","volume":"28","author":"Becker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","article-title":"Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse","volume":"99","author":"Hubmann","year":"2014","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Matthews, A.H., Pratz, K.W., and Carroll, M.P. (2022). Targeting Menin and CD47 to address unmet needs in acute myeloid leukemia. Cancers, 14.","DOI":"10.3390\/cancers14235906"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2009-04-216606","article-title":"Leukemogenic transformation by HOXA cluster genes","volume":"115","author":"Bach","year":"2010","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-021-01057-7","article-title":"Structure, function and inhibition of critical protein\u2013protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-025-02161-5","article-title":"Revumenib: First Approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_17","unstructured":"Shukla, N., Guest, S., Tasian, K., Breese, E., Schafer, J., DiPersio, G., Issa, G.C., Silverman, B., Stieglitz, B., and Pollard, J. (2024). Safety and Activity of Revumenib Combination with Fludarabine\/Cytarabine (FLA) in Patients with Relapsed\/Refractory Acute Leukemias, EHA."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zeidner, J.F., Lin, T.L., Welkie, R.L., Curran, E., Koenig, K., Stock, W., Madanat, Y.F., Swords, R., Baer, M.R., and Blum, W. (2025). Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J. Clin. Oncol., Online ahead of print.","DOI":"10.1200\/JCO-25-00914"},{"key":"ref_19","unstructured":"Issa, G., Ambinder, A.J., Xiao, W., Manalis, S., Shalek, A.K., Gondek, L.P., Kentsis, A., Short, N.J., Daver, N., and Ning, J. (2024, January 7\u201310). A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib: Trial in Progress. Proceedings of the 2024 American Society of Hematology Annual Meeting, San Diego, CA, USA."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2022-164849","article-title":"The Menin Inhibitor SNDX-5613 (Revumenib) Leads to Durable Responses in Patients with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase 1 Study","volume":"140","author":"Issa","year":"2022","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Arellano, M.L., Thirman, M.J., DiPersio, J.F., Heiblig, M., Stein, E.M., Schuh, A.C., Zucenka, A., De Botton, S., Grove, C.S., and Mannis, G.N. (2025). Menin Inhibition with Revumenib for NPM1-Mutated Relapsed or Refractory Acute Myeloid Leukemia: The AUGMENT-101 Study. Blood, Online ahead of print.","DOI":"10.1182\/blood.2025028357"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"LBA-5","DOI":"10.1182\/blood-2023-192042","article-title":"Revumenib Monotherapy in Patients with Relapsed\/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal AUGMENT-101 Phase 2 Study","volume":"142","author":"Aldoss","year":"2023","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2024-194384","article-title":"Updated Results and Longer Follow-Up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R\/R) KMT2Ar Acute Leukemia","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2022.02.004","article-title":"Distinct Pathologic Feature of Myeloid Neoplasm with t(v;11p15); NUP98 Rearrangement","volume":"123","author":"Lauw","year":"2022","journal-title":"Hum. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in Relapsed or Refractory Acute Myeloid Leukaemia (KOMET-001): A Multicentre, Open-Label, Multi-Cohort, Phase 1 Trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/blood-2024-199170","article-title":"Ziftomenib Combined with Venetoclax\/Azacitidine in Relapsed\/Refractory NPM1-M or KMT2A-R Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007","volume":"144","author":"Fathi","year":"2024","journal-title":"Blood"},{"key":"ref_27","unstructured":"Erba, H., Wang, E., Fathi, A., Roboz, G., Madanat, Y., Strickland, S., Balasubramanian, S., Mangan, J., Pratz, K., and Advani, A. (2025, January 12\u201315). Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-M or KMT2A-R Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. Abstract 4159213. Proceedings of the EHA 2025 Congress, Milan, Italy."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2023-190475","article-title":"KOMET-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed\/Refractory Acute Myeloid Leukemia","volume":"142","author":"Goldberg","year":"2023","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical Efficacy of the Potent, Selective Menin-KMT2A Inhibitor JNJ-75276617 (Bleximenib) in KMT2A- and NPM1-Altered Leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1182\/blood-2022-168921","article-title":"Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, as Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia","volume":"140","author":"Kwon","year":"2022","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood-2023-172422","article-title":"A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed\/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations","volume":"142","author":"Jabbour","year":"2023","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed\/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2024-207072","article-title":"Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations","volume":"144","author":"Recher","year":"2024","journal-title":"Blood"},{"key":"ref_34","unstructured":"Wei, A.H., Searle, E., Aldoss, I., Pierola, A.A., Alonso-Dominguez, J.M., Curtis, M., Daskalakis, N., Della Porta, M.G., D\u00f6hner, H., and D\u2019Souza, A. (2024). A Phase 1b Study of the Menin-KMT2A Inhibitor JNJ-75276617 in Combination with Venetoclax and Azacitidine in Relapsed\/Refractory Acute Myeloid Leukemia with Alterations in KMT2A or NPM1. Abstract 422237, EHA Library."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2021-152050","article-title":"Preclinical evaluation of a novel orally bioavailable menin-MLL interaction inhibitor, DSP-5336, for the treatment of acute leukemia patients with MLL-rearrangement or NPM1 mutation","volume":"138","author":"Eguchi","year":"2021","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 results: First-in-human phase 1\/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12935-023-02877-y","article-title":"A novel menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1","volume":"23","author":"Numata","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41568-021-00367-9","article-title":"MYC protein interactors in gene transcription and cancer","volume":"21","author":"Lourenco","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1182\/blood-2023-173149","article-title":"Covalent menin inhibitor BMF-219 in patients with relapsed or refractory (R\/R) acute leukemia: Preliminary phase 1 data from the COVALENT-101 study","volume":"142","author":"Lancet","year":"2023","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s43018-022-00366-1","article-title":"IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia","volume":"3","author":"Aubrey","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2023021105","article-title":"Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML","volume":"143","author":"Bourgeois","year":"2024","journal-title":"Blood"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/7\/227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:12:42Z","timestamp":1760033562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/7\/227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["diseases13070227"],"URL":"https:\/\/doi.org\/10.3390\/diseases13070227","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]}}}